n UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                        March 1, 2010 (February 28, 2010)
                Date of Report (Date of earliest event reported)


                              ENOX BIOPHARMA, INC.
             (Exact name of registrant as specified in its charter)

                                     NEVADA
         (State or other jurisdiction of incorporation or organization)

                          Commission File No. 000-53486

                                   26-0477124
                     (I.R.S. Employer Identification Number)

                           Suite 303-1687 W. Broadway
                                Vancouver V6J1X2
                                     Canada
                    (Address of principal executive offices)

                                 (604) 637-9744
              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(C)under the
    Exchange Act (17 CFR 240.13e-4(C))

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
           APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF
           CERTAIN OFFICERS.

Effective  as of February 28,  2010,  the Board of Directors of Enox  Biopharma,
Inc.  ("Enox," or the "Company")  appointed Mr. Amir Avniel,  36, as Chairman of
the Board of the Company.  No arrangements or  understandings  exist between Mr.
Avniel and any other person pursuant to which he was selected as a director.

Prior to joining the Company,  Mr. Avniel served as Chief  Executive  Officer of
Rosetta  Genomics  (Nasdaq:  ROSG) from April 2006 until  October  2009,  and as
Rosetta  Genomics'  President  from May 2005 until October 2009. Mr. Avniel also
served in other senior management positions at Rosetta Genomics, including Chief
Technology  Officer and Chief Operating  Officer,  from May 2001 to May 2005. Mr
Avniel has been named  co-author of 20 patent  applications.  Mr. Avniel studied
computer science at the Academic College of Tel Aviv - Jaffa,  Israel.  Prior to
his academic studies, he served as an officer in the Israel Defense Force, where
he was awarded four commendations for excellence.

Mr.  Avniel  will be  compensated  on terms to be  considered  by the  Board and
determined by mutual  agreement  with Mr.  Avniel,  and may include,  but not be
limited to, options to purchase an aggregate of approximately 1.8 million shares
of the Company's common stock.


                                       2

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                       ENOX BIOPHARMA, INC.


Date: March 1, 2010                    By: /s/ Prof. Yossef Av-Gay
                                           -------------------------------------
                                           Prof. Yossef Av-Gay
                                           President and Chief Executive Officer



                                       3